-Brings Broad Expertise and Strong Leadership Skills in Developing and Refining Innovative Life Sciences Systems-
PHILADELPHIA, Jan. 9 /PRNewswire/ -- BioNanomatrix, Inc., a developer of breakthrough nanoscale platforms for molecular diagnostics, personalized medicine and biomedical research, today announced the appointment of Michael Kochersperger as vice president of engineering. Mr. Kochersperger has over two decades of product development and commercialization experience at leading life sciences tools companies. He will lead the team focusing on the commercial design and development of BioNanomatrix's breakthrough nanoscale whole genome imaging and analysis system for multiple markets, including research, diagnostics and personalized medicine.
"Michael is an exceptional addition to the BioNanomatrix leadership team," said Dr. Michael Boyce-Jacino, chief executive officer of BioNanomatrix. "He has broad product-focused engineering expertise combined with a record of success in delivering innovative life sciences systems to market on time and within budget. Michael's engineering experience and leadership skills will be invaluable as we focus on developing commercial versions of our nanoscale whole genome imaging and analysis technology."
BioNanomatrix is applying its expertise in nanochips, nanodevices and nanosystems to develop its platform technology providing fast, comprehensive and low-cost analysis of genomic, epigenomic and proteomic information with sensitivity at the single-molecule level. Among its current development efforts is a federally funded project in partnership with Complete Genomics Inc. for very low-cost sequencing of the human genome.
"BioNanomatrix's technology has the potential to be transformative, allowing scientists to analyze genomic material much faster, more cost-effectively and with far better accuracy and resolution than existing methods," said Mr. Kochersperger. "I look forward to working with the BioNanomatrix team to commercialize products based on our revolutionary technology, which has the potential to make whole genome imaging and analysis accessible for the first time for a wide range of research and diagnostic applications."
Prior to joining BioNanomatrix, Michael was vice president of engineering at New Brunswick Scientific, a division of Eppendorf, where he oversaw global product development efforts, helping to revitalize the company's entire product portfolio in less than six years. Previously, he was director of SNP-IT genotyping research and development at Orchid Biosciences, where he led the development and commercialization of ultra-high-throughput microarray-based genotyping systems. Prior to Orchid, Michael was project manager for the development of a combinatorial chemistry synthesis system at Applera. Previously, he was project team lead for protein sequencing system development at Perkin Elmer, where he oversaw the development and improvement of several systems. Earlier, Michael was at Applied Biosystems, where he held positions of increasing responsibility, managing mass spectrometry and protein sequencing projects and providing technical support. He has authored a number of scientific publications and holds three patents. Michael received a B.S. in chemical engineering from Ohio State University.
BioNanomatrix is developing breakthrough nanoscale whole genome imaging and analytic platforms for applications in genetic diagnostics, personalized medicine and biomedical research. The company is applying its expertise in nanochips, nanodevices and nanosystems to develop its patented platform technology to provide fast, comprehensive, and low-cost analysis of genomic, epigenomic and proteomic information with sensitivity at the single-molecule level. Its current development efforts include a federally funded project to sequence the human genome at a cost of $100. BioNanomatrix's technologies are licensed exclusively from Princeton University. Founded in 2003, the company is headquartered in Philadelphia, Pennsylvania. For more information, visit: www.BioNanomatrix.com.
Contact: Barbara Lindheim GendeLLindheim BioCom Partners 212 918-4650
SOURCE BioNanomatrix, Inc.